Spectrum Pharmaceuticals Announces Promotion Of Joseph Turgeon To Senior Vice President And Chief Commercial Officer As Company Builds On Recent Commercial Reorganization To Advance Growth And Market Penetration Over The Next Five Years

The Company also announced today the further expansion of its sales and marketing leadership, with the appointments of Robert Fralin as Vice President of Sales and Al DeJesus as Executive Director, Marketing. Previously, Mr. Fralin served as Executive Director of Amgen’s Bone Health Business Unit and prior to that, as Executive Director of Amgen’s Oncology Business Unit, which had annual revenues exceeding $1 billion. Mr. DeJesus is the former Executive Director of Amgen’s Global Oncology Marketing, with responsibilities including worldwide planning for Amgen’s oncology products and global partnerships. Both individuals will report directly to Mr. Turgeon.

Mr. Turgeon continued, “Spectrum continues to attract top talent, and the appointments of Robert Fralin and Al DeJesus further demonstrate the excitement we feel at the company at the start of 2013. Each brings their unique perspectives and expertise, and each will be invaluable to the success and expansion of Spectrum’s presence in the U.S. and other key territories where we will gain a presence in the oncology market.”

In November, 2012, Spectrum undertook a strategic strengthening of its sales force in the U.S., implementing a structure of six geographic regions and expanding the sales team to 60 professionals in order to effectively and efficiently add more oncology products in the future. In the near term, multiple synergies are anticipated, including from the fact that the sales force will market ZEVALIN and FOLOTYN to the same physicians. Further, each regional manager is empowered to align sales resources and tailor promotional and other physician and patient support initiatives to meet our customers' needs, allowing Spectrum to become even more of a customer-facing commercial organization. The realignment of existing resources is expected to result in a significantly greater hematology and oncology footprint, increased promotional reach, and more efficient physician engagement.

About FUSILEV® (levoleucovorin) for injection

FUSILEV, a novel folate analog, is approved as a ready-to-use solution (FUSILEV Injection), and as freeze-dried powder (FUSILEV for Injection). FUSILEV is indicated for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. FUSILEV is also indicated for rescue after high-dose methotrexate therapy in osteosarcoma. FUSILEV is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists. FUSILEV, under various trade names, is marketed outside the United States by Pfizer, Sanofi-Aventis, and Takeda.

« First ‹ Previous 1 2 3 4 5 6 Next › Last »